ArticleCancers2022
A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 31 citations in OpenAlex.
- Dupilumab as an Effective Adjuvant Therapy for Corticosteroid-Refractory Lichenoid-Bullous Dermatitis Secondary to Pembrolizumab.The Australasian journal of dermatology · 2026Article
- Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving Immunotherapy.Life (Basel, Switzerland) · 2026Article
- Mendelian Randomization and Experimental Validation Identify Key Immune Signatures in Bullous Pemphigoid.Clinical, cosmetic and investigational dermatology · 2026Article
- The immunophenotype of immune checkpoint-induced bullous pemphigoid: a cohort study.Cancer immunology, immunotherapy : CII · 2025Article
- Article
- Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series.The oncologist · 2025Article
- Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review.Biomedicines · 2025Review
- Application of multivalent aptamers in tumor diagnosis, analysis and therapy (Review).Oncology letters · 2025Review
- Steroid resistant bullous pemphigoid induced by pembrolizumab in a patient with metastatic lung adenocarcinoma: case report and review of the literature.Discover oncology · 2025Article
- Research in practice: Immune checkpoint inhibitor related autoimmune bullous dermatosis.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Review
- A case of pembrolizumab-induced bullous pemphigoid treated with dupilumab.Skin health and disease · 2025Article
- An Adverse Double-Hit by Pembrolizumab: A Case Report of Bullous Pemphigoid and Pneumonitis.Journal of medical cases · 2025Article
- Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.International journal of molecular sciences · 2024Review
- Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.Medicina (Kaunas, Lithuania) · 2024Review
- The possible and intriguing relationship between bullous pemphigoid and melanoma: speculations on significance and clinical relevance.Frontiers in immunology · 2024Review
- Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience.Journal of personalized medicine · 2023Article
- Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review.Medicina (Kaunas, Lithuania) · 2023Review
- Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?Clinics and practice · 2023Article
- Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer.Biomedicines · 2023Article
- Carpal Tunnel Syndrome Associated with Immune Checkpoint Inhibitors.Journal of personalized medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors are a class of cancer treatment drugs that stimulate the immune system's ability to fight tumor cells. These drugs are monoclonal antibodies targeting im-mune-inhibiting proteins on cancer cells, such as CTLA-4 and PD-1/PD-L1. Immune checkpoint inhibitors cause many immune-related adverse events. Cutaneous toxicities are of the most common adverse effects and occur with a range of severity. Bullous Pemphigoid is a rare adverse event with a high impact on quality of life that may occur after immune checkpoint inhibitor treatment. In this article, we investigate current research on immune checkpoint inhibitors, cutaneous adverse events, and common presentations and treatments, with a specific focus on Bullous Pemphigoid, its characteristics, onset timing, and treatment. Significant findings include a negative skew in the onset of presentation. Furthermore, we describe exclusive cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.